Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination

• DOI: 10.1002/rth2.12658
• Publication Date: 2022-02-08T07:58:24Z
• Authors: William Deucher; Senthil Sukumar; Spero R. Cataland
• Keywords: ADAMTS13

De novo and relapsed immune-mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to occurred following severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccination. Here, we present a case of 28-year-old woman who received the tozinameran (BNT162b2, Pfizer-BioNtech) vaccine for COVID-19 experienced an iTTP relapse during longitudinal follow-up. She 30 months after her initial diagnosis, while she was in clinical remission. not complete ADAMTS-13 remission, as had undetectable activity follow-up except one isolated measurement 48%. Shortly vaccination, developed complaints bruising, petechiae, ataxia, episode slurred speech. Laboratory testing demonstrated thrombocytopenia, schistocytes, eventually activity. successfully treated with caplacizumab, rituximab, corticosteroids without plasma exchange. achieved remission treatment. We recommend caution administration vaccines survivors severely deficient